3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Gliosarcoma
1
Glioblastoma
1
Interventions
Cyclophosphamide
5
regorafenib
3
Temozolomide
3
Magnetic Resonance Spectroscopy
3
Irinotecan
3
Etoposide
3
Doxorubicin
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
palbociclib
2
ivosidenib
2
etoposide phosphate
2
cabozantinib
2
X-Rays
2
Vincristine
2
Specimen Handling
2
Sirolimus
2
Radiation
2
Phantoms, Imaging
2
Nuclear Medicine Department, Hospital
2
Ifosfamide
2
Biopsy
2
tazemetostat
1
racemetyrosine
1
pembrolizumab
1
olaparib
1
larotrectinib
1
ganitumab
1
erdafitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Sarcoma, Ewing
×
CLR1404
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled